Cumberland Pharmaceuticals Inc. (CPIX)
| Market Cap | 112.82M +141.6% |
| Revenue (ttm) | 44.30M +120.8% |
| Net Income | -10.92M |
| EPS | -0.74 |
| Shares Out | 14.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,616 |
| Open | 7.57 |
| Previous Close | 7.51 |
| Day's Range | 7.41 - 7.74 |
| 52-Week Range | 1.85 - 9.28 |
| Beta | 0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sod... [Read more]
Financial Performance
In 2025, CPIX's revenue was $44.52 million, an increase of 17.57% compared to the previous year's $37.87 million. Losses were -$2.84 million, -56.23% less than in 2024.
Financial StatementsNews
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nas...
Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2026
A major strategic transaction provided $100M in cash, enabling a pivot to clinical development and a special $1.50/share dividend. The company now focuses on advancing ifetroban programs in rare diseases, with strong financial reserves and multiple clinical milestones expected in 2026.
Cumberland Pharmaceuticals Earnings release: Q2 2026
Cumberland Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Cumberland Pharmaceuticals Quarterly report: Q2 2026
Cumberland Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, ...
Cumberland announces special dividend of $1.50 per share
Cumberland (CPIX) Pharmaceuticals Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company’s common stock. The dividend will be payable on July…
Cumberland board authorizes $5M share repurchase program
In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5M in Cumberland (CPIX) shares over time. Several Board members will also be…
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc....
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
TORONTO, July 1, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic tr...
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. ...
Cumberland shares updated FIGHT DMD trial results
Cumberland (CPIX) Pharmaceuticals shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy heart disease, at the annual Parent...
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: C...
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- ...
RedHill Biopharma Announces Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- Re...
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young c...
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Cumberland announces data from Phase 2a clinical trial of ifetroban
Cumberland (CPIX) Pharmaceuticals and Vanderbilt Health announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors. The study’s primary safety endpoint w...
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Positive Results from Phase 2a Clinical Trial Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors Trial revealed promising efficac...
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d...
Cumberland announces launch of Vibativ in China
Cumberland (CPIX) announced the launch of its Vibativ – telavancin – injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals. The launch follows an ...
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical market NASHVILLE, Tenn.,...
Cumberland Pharmaceuticals Proxy statement: Proxy filing
Cumberland Pharmaceuticals filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Cumberland Pharmaceuticals Proxy statement: Proxy filing
Cumberland Pharmaceuticals filed a proxy statement on May 15, 2026, providing details for shareholder voting and corporate governance matters.
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Phar...
Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 5% year-over-year (excluding a prior milestone), with positive cash flow and a net loss of $3.3 million. A $100 million Apotex deal will shift focus to pipeline innovation, while FDA approvals and new product launches drive momentum.